Ethionamide pharmacokinetics in multidrugresistant tuberculosis patients with and without HIVinfection

Simple item page
dc.contributor.advisorMugabo, Pierre
dc.contributor.authorEzeukwu, Ifeoma Patricia
dc.date.accessioned2018-08-02T12:27:41Z
dc.date.accessioned2024-05-15T07:42:56Z
dc.date.available2018-08-02T12:27:41Z
dc.date.available2024-05-15T07:42:56Z
dc.date.issued2017
dc.descriptionMagister Pharmaceuticae - Mpharmen_US
dc.description.abstractMany studies have investigated the pharmacokinetics (PK) of anti-tuberculosis drugs in tuberculosis patients. However, currently in South Africa, no studies have been done on ethionamide (ETH) PK in adult MDR-TB patients that are infected with HIV and those without HIV infection. Therefore, the objective of this current study was firstly, to find out ethionamide plasma concentration using the LC-MS method; secondly, to evaluate and compare the pharmacokinetics of ethionamide in MDR-TB patients infected with and without HIV infection; thirdly, to examine the effects of ARVs and kidney impairment on the PK of ethionamide and fourthly, to find out the consequence of sex and age on ETH PK parameters.en_US
dc.identifier.urihttps://hdl.handle.net/10566/15163
dc.language.isoenen_US
dc.publisherUniversity of the Western Capeen_US
dc.rights.holderUniversity of the Western Capeen_US
dc.subjectMultidrug-resistant tuberculosisen_US
dc.subjectHuman immunodeficiency virusen_US
dc.subjectMycobacterium tuberculosisen_US
dc.subjectAntiretroviral agentsen_US
dc.subjectEthionamideen_US
dc.subjectPharmacokineticsen_US
dc.subjectPlasma concentrationsen_US
dc.subjectLiquid chromatographyen_US
dc.subjectMass spectrometryen_US
dc.titleEthionamide pharmacokinetics in multidrugresistant tuberculosis patients with and without HIVinfectionen_US
dc.typeThesisen_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Ezeukwu_MPHARM_NSC_2017.pdf
Size:
2.21 MB
Format:
Adobe Portable Document Format
Download

Collections

Magister Pharmaceuticae - MPharm